Anastasios Konidaris serves as the Executive Vice President and Chief Financial Officer at Amneal Pharmaceuticals Inc Class A, a leading global pharmaceuticals company. With a robust background in finance and strategic management, Konidaris has been instrumental in steering Amneal's financial strategies and growth initiatives. He joined Amneal in 2019, bringing with him a wealth of experience from previous high-level positions in the pharmaceutical and healthcare sectors. Before joining Amneal, Konidaris held significant roles that shaped his expertise in financial leadership. He was the Chief Financial Officer at PRA Health Sciences, where he played a pivotal role in the company's growth and eventual sale to ICON plc for $12 billion. His career also includes a tenure as the CFO of the Pharmaceuticals and Medical Devices division at Covidien, now part of Medtronic, where he managed financial operations across multiple global markets. Konidaris's strategic vision and financial acumen have been key in driving Amneal's expansion and innovation in the competitive pharmaceuticals industry. In his current role at Amneal, Konidaris oversees the company's financial planning, accounting, and investor relations, ensuring that Amneal remains financially robust and strategically positioned for future growth. Under his leadership, Amneal has successfully navigated complex market dynamics, including regulatory challenges and competitive pressures. His commitment to excellence and strategic foresight continues to be a driving force behind Amneal's mission to improve patient health and well-being through the development and distribution of high-quality pharmaceutical products.